IL6 and stage 5 chronic kidney disease: Recently, a causal role for IL-6 in systemic atherothrombosis and aneurysm formation and the potential role of IL-6 inhibition in stable coronary disease, acute coronary syndromes, heart failure, and the atherothrombotic complications associated with chronic kidney disease and end-stage renal failure have been reported [13].